유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumabs - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents for dermatitis, excluding corticosteroids - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiple mieloma - antineoplastiski līdzekļi - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glikogēna uzglabāšanas slimības ii tipa - citas gremošanas trakta un metabolisma produkti, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin aspart - cukura diabēts - cukura diabēts - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imūnsupresanti - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).

라트비아 - 라트비아어 - Zāļu valsts aģentūra

sanofi winthrop industrie, france - zolpidēma tartrāts - apvalkotā tablete - 10 mg

라트비아 - 라트비아어 - Zāļu valsts aģentūra

sanofi-aventis latvia, sia, latvija - betaksolola hidrohlorīds - apvalkotā tablete - 20 mg

라트비아 - 라트비아어 - Zāļu valsts aģentūra

sanofi pasteur, france - poliomielīta vakcīna (inaktivēta) - suspensija injekcijām pilnšļircē - 0,5 ml/deva

라트비아 - 라트비아어 - Zāļu valsts aģentūra

sanofi winthrop industrie, france - alfuzosīna hidrohlorīds - ilgstošās darbības tablete - 10 mg

라트비아 - 라트비아어 - Zāļu valsts aģentūra

sanofi b.v., netherlands - imūbnglobulīns pret cilvēka timocītiem, truša - pulveris infūziju šķīduma pagatavošanai - 25 mg